Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others

Cleve Clin J Med. 2011 Apr;78(4):243-57. doi: 10.3949/ccjm.78a.10145.

Abstract

Genetics may account for much of the variability in our patients' responses to drug therapies. This article offers the clinician an up-to-date overview of pharmacogenomic testing, discussing implications and limitations of emerging validated tests relevant to the use of warfarin (Coumadin), clopidogrel (Plavix), statins, tamoxifen (Nolvadex), codeine, and psychotropic drugs. It also discusses the future role of pharmacogenomic testing in medicine.

Publication types

  • Review

MeSH terms

  • Clopidogrel
  • Cytochrome P-450 Enzyme System / genetics*
  • Genetic Testing / methods*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Pharmacogenetics / methods*
  • Psychotropic Drugs / pharmacology
  • Tamoxifen / pharmacology
  • Ticlopidine / analogs & derivatives
  • Ticlopidine / pharmacology
  • Warfarin / pharmacology

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Psychotropic Drugs
  • Tamoxifen
  • Warfarin
  • Cytochrome P-450 Enzyme System
  • Clopidogrel
  • Ticlopidine